In May 2022 FDA approved a test to easily detect Amyloid Beta 42/40 ratio (Aβ 42/40) and Apolipoprotein E proteotype (equivalent to ApoE genotype) in blood samples, Artificial intelligence approaches such as machine learning may facilitate the early diagnosis of AD using surrogate biomarkers through the recognition of voice profiles (10), beta-amyloid accumulation on brain PET (11), or certain characteristic profiles on brain MRI such as medial temporal atrophy (12). This evidence concerns the gene APOE and Alzheimer disease.